This review highlights clinical efficacy of PTH (1–34) for improving bone health in breast cancer, suggesting reduced fracture risk and insight into osteoblast signaling pathways.
Key Points
Bone health improvement linked to clinical efficacy of PTH (1–34) in breast cancer patients, indicating reduced fracture risk.
Osteoporosis and pathologic fractures are serious concerns for women after breast cancer treatment, complicating survivorship.
Analysis focused on the role of osteoblasts and cyclic adenosine monophosphate signaling pathways related to PTH (1–34).
Findings suggest PTH (1–34) may provide a new therapeutic avenue for managing bone metastasis and related complications.